Effect of the H 1 -antihistamine clemastine on PACAP38 induced migraine
Research output: Contribution to journal › Journal article › Research › peer-review
Objective: To investigate the effect of the H 1 -antihistamine clemastine on the migraine-inducing abilities of pituitary adenylate cyclase activating peptide-38. Methods: We conducted a double-blind, randomized, placebo controlled two-way cross-over study. Twenty migraine without aura patients were randomly allocated to receive bolus clemastine 2 mg (1 mg/ml) or bolus saline 2 ml intravenously over 2 min on two study days. Following each bolus injection, 10 pmol/kg/min of pituitary adenylate cyclase activating peptide-38 was administered intravenously over 20 min. We recorded migraine/headache characteristics every 10 min until 90 min after the start of infusion, and collected blood to investigate mast cell degranulation and the inflammation markers tryptase and tumor necrosis factor-alpha before and after infusion of pituitary adenylate cyclase activating peptide-38. Results: After clemastine pretreatment, five out of 20 participants developed a migraine-like attack in response to a pituitary adenylate cyclase activating peptide-38 infusion compared to nine out of 20 after placebo pretreatment (p = 0.288). Following clemastine pretreatment, 15 out of 20 participants reported headache in response to a pituitary adenylate cyclase activating peptide-38 infusion, whereas 19 out of 20 participants did so following placebo pretreatment (p = 0.221). We found no difference in area under the curve 12 h for headache intensity between the two experimental days (p = 0.481). We found no difference in area under the curve 180 min for tryptase (p = 0.525) or tumor necrosis factor-alpha (p = 0.487) between clemastine and placebo pretreatment days. Conclusion: H 1 -antihistamine, clemastine, failed to prevent migraine or headache after pituitary adenylate cyclase activating peptide-38 infusion, thus making a role for histamine release or mast cell degranulation in pituitary adenylate cyclase activating peptide-38-induced migraine less likely.
Original language | English |
---|---|
Journal | Cephalalgia |
Volume | 39 |
Issue number | 5 |
Pages (from-to) | 597-607 |
Number of pages | 11 |
ISSN | 0333-1024 |
DOIs | |
Publication status | Published - 2019 |
- antihistamine, mast cells, migraine, PAC receptor, PACAP38
Research areas
ID: 235783415